Imunon, Inc. quarterly report, Q2 FY2017

Business context and reporting period

Celsion Corporation’s unaudited Form 10-Q covers the quarter and six months ended June 30, 2017. The company is a development-stage oncology drug company with no meaningful product sales. Its lead candidate, ThermoDox, was in Phase III testing for liver cancer and Phase II testing for recurrent chest-wall breast cancer; GEN-1 was in early-stage ovarian cancer testing.

Key financial metrics

MetricThree months ended June 30, 2017Six months ended June 30, 2017
Licensing revenue$125,000$250,000
Research and development$3.05 million$6.52 million
General and administrative$1.65 million$3.12 million
Net loss$4.89 million$10.05 million
Net loss attributable to common shareholders$5.24 million$10.40 million
Basic and diluted loss per share$0.79$1.75

Revenue was amortization of a prior Hisun technology payment, not product sales. Operating margins are not meaningful given the company’s development-stage status and minimal revenue.

  • Cash and cash equivalents were $3.63 million at June 30, up from $2.62 million at December 31, 2016; available-for-sale investments were zero, versus $1.68 million at year-end.
  • Operating cash use was $7.33 million for the first half, compared with $8.99 million in 2016. Investing activities provided $1.76 million and financing activities provided $6.57 million.
  • Current assets were $3.74 million and current liabilities $6.96 million, a $3.22 million working-capital deficit. Stockholders’ equity was $6.65 million; accumulated deficit was $251.43 million.
  • The Hercules loan, including end-of-term charges, was paid in full in June. No loan balance remained at period-end.

Changes versus prior comparable periods

  • Second-quarter net loss increased to $4.89 million from $4.53 million in 2016, despite operating expenses declining 3.5% to $4.70 million. The change in the earn-out liability moved from a $409,000 benefit in Q2 2016 to a $292,000 non-cash charge in Q2 2017.
  • First-half net loss improved to $10.05 million from $10.25 million. Operating expenses fell 5.2% to $9.64 million, including lower R&D and G&A costs. The earn-out revaluation was a $576,000 charge in 2017 versus a $106,000 benefit in 2016.
  • First-half financing included $4.25 million net proceeds from common stock sales and $4.92 million from warrant exercises, partly offset by $2.60 million in debt principal and end-of-term payments. Warrant repricings generated about $3.0 million gross proceeds and a $346,000 deemed dividend.

Outlook, commentary and risks

  • Management disclosed substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing recurring losses, capital needs and lack of committed financing. The filing gives differing estimates for the post-financing cash runway: through year-end 2017 in one discussion and into Q1 2018 in another.
  • After quarter-end, the company reported a July registered direct offering and concurrent warrant placement totaling approximately $5.04 million gross. Management also cited a $7.5 million ATM facility and plans to seek further equity, debt, partnerships or licensing. Additional capital may be dilutive; without funding, programs could be delayed, reduced or terminated.
  • On August 7, 2017, the OPTIMA Study monitoring committee recommended continuing the trial as planned after reviewing the first 275 patients. Enrollment was reported above 60%, with completion expected by mid-2018 based on then-current rates. The trial’s hypothesis relies partly on post-hoc subgroup analyses of the earlier HEAT study, which failed its primary progression-free-survival endpoint; those retrospective findings are uncertain.
  • The company reported positive early OVATION study observations, but these are from a small, early-stage study and do not establish efficacy. Clinical, regulatory, manufacturing, financing, dilution, intellectual-property, competition and Nasdaq-listing risks remain material. The filing reported no legal proceedings and stated disclosure controls were effective.
  • A 1-for-14 reverse stock split took effect in May 2017; historical share and per-share figures were adjusted. The $13.76 million EGEN earn-out milestone liability is Level 3 fair value and depends on milestone assumptions.

Important facts for investors to verify

  1. Actual cash runway after the July financing, operating burn, and whether additional capital was raised on acceptable terms.
  2. OPTIMA enrollment and timeline, trial conduct and data quality, and the eventual results of the primary overall-survival endpoint.
  3. Whether ThermoDox’s post-hoc HEAT findings support the current trial hypothesis, given HEAT’s failure on its primary endpoint.
  4. GEN-1’s progress beyond early-stage observations and the cost and timing of planned studies.
  5. Potential dilution from outstanding warrants, options, future offerings and the ATM, as well as the assumptions underlying the EGEN earn-out liability.